Safety, Tolerability, and Preliminary Efficacy of Soquelitinib in Participants With Moderate to Severe AD

Part of paid clinical trials in Birmingham, Alabama.

Sponsor
Corvus Pharmaceuticals, Inc.
Study ID
NCT06345404
Phase
PHASE1
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Soquelitinib — DRUG
    Tablets
  • Placebo — DRUG
    Soquelitinib matching placebo tablets

Study Details

Safety, tolerability, and preliminary efficacy of soquelitinib in participants with moderate to severe AD

Key Dates

Start date
Apr 16, 2024
Status verified
Mar 2026
Primary completion
Jan 28, 2026
Completion
Feb 24, 2026

Study Design

Enrollment
82 participants (actual)
Allocation
RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT

Arms

  • Experimental: Soquelitinib Dose Escalation and Dose Expansion
    In Dose Escalation, participants will receive soquelitinib tablets orally at one of three dose levels (100 mg twice daily, 200 mg once daily, 200 mg twice daily) for 28 days. In Dose Expansion, participants will receive soquelitinib tablets orally at a dose selected from the dose escalation part of the study, for 56 days
  • Placebo Comparator: Placebo
    Participants in the Dose Escalation part of the study will receive placebo tablets orally once daily or twice daily for 28 days. Participants in the Dose Expansion part of the study will receive placebo tablets orally once daily or twice daily for 56 days

Primary Outcome Measure

Incidence of adverse events, changes in laboratory values, vital signs, and electrocardiograms [ Time Frame: Up to 30 days after last intervention administration ]

Locations (16)

FacilityCityStateZIPSite coordinators
Clinical Site 5BirminghamAlabama35244-
Clinical Site 9TucsonArizona85704-
Clinical Site 3North Little RockArkansas72117-
Clinical Site 2FremontCalifornia94538-
Clinical Site 7Palo AltoCalifornia94063-
Clinical Site 13PomonaCalifornia91767-
Clinical Site 10Castle RockColorado80109-
Clinical Site 6TampaFlorida33615-
Clinical Site 11BrooklynNew York11203-
Clinical Site 12New YorkNew York10075-
Clinical Site 16New YorkNew York10023-
Clinical Site 15Mayfield HeightsOhio44124-
Clinical Site 1Camp HillPennsylvania17011-
Clinical Site 8PhiladelphiaPennsylvania19103-
Clinical Site 4FriscoTexas75034-
Clinical Site 14San AntonioTexas78213-

Find similar trials in Birmingham, AL

By condition
Atopic dermatitis / eczema
By specialty
DermatologyRheumatologyAutoimmune disease
By research site
Clinical· Birmingham, ALClinical· Tucson, AZClinical· North Little Rock, ARClinical· Fremont, CAClinical· Palo Alto, CAClinical· Pomona, CA

Related Studies